# Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

> **NCT00914628** · PHASE3 · TERMINATED · sponsor: **AGC Biologics S.p.A.** · enrollment: 92 (actual)

## Conditions studied

- Acute Leukemia (Category)

## Interventions

- **GENETIC:** HSV-Tk
- **OTHER:** T-cell depleted or T-cell replete strategies

## Key facts

- **NCT ID:** NCT00914628
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04-12
- **Primary completion:** 2019-11-30
- **Final completion:** 2019-11-30
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** EMA withdrew the marketing Authorisation at the request of AGC Biologics S.p.A (formerly MolMed S.p.A), which decided to permanently discontinue the marketing of the product for commercial reasons
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00914628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00914628, "Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00914628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*